Rapid Readouts

HSCT With Omidubicel Achieved Robust Immune Reconstitution and Lower Rates of Severe Infection Compared to UCB Transplantation

February 24th 2022

Expert hematologist/oncologist Paul Szabolcs, MD, reviews positive data from a clinical trial comparing hematopoietic stem cell transplantation and omidubicel with standard cord blood transplantation.

Trending on CGTlive®

Rapid Readouts

HSCT With Omidubicel Achieved Robust Immune Reconstitution and Lower Rates of Severe Infection Compared to UCB Transplantation

Trending on CGTlive®

FDA Decisions to Look For in 1H 2026

Around the Helix: Cell and Gene Therapy Company Updates – January 7, 2026

FDA Activity Recap: December 2025 Features Multiple Approvals, RMAT Designation, and More

Interview Highlights From ASH's 2025 Meeting

Ultragenyx Finishes Rolling Submission of BLA for Glycogen Storage Disease Gene Therapy DTX401